Vis enkel innførsel

dc.contributor.advisorKlingenberg, Claus
dc.contributor.authorMosulet, George Vladimir
dc.date.accessioned2018-08-21T12:54:38Z
dc.date.available2018-08-21T12:54:38Z
dc.date.issued2018-06-04
dc.description.abstractAbstract Background: The aim for this thesis has been to investigate the use of cannabinoids in treatment of epilepsy. The topic is currently under a lot of discussion in many countries, and there is a high pressure on the health community to make these substances available from both patients, their families and politicians. This thesis consists of two parts. First, I aimed to review the literature on this topic over the last 5 years. Secondly, we performed an international survey to investigate how much knowledge, clinical experience or perhaps lack or experience caregivers have on this topic. Material and Methods: Clinical and medical databases were searched and the studies that matched inclusion/exclusion criteria were analysed. A web-based survey was sent out to neuro-paediatricians in Norway, Sweden, Denmark and Germany. Results: The results from the literature show that especially cannabidiol (CBD) has an effect on seizure reduction, mainly shown in people with treatment resistant epilepsy (TRE). We received response from 86 neuro-paediatricians, a low response rate (~14 % ). Therefore, one can question how representative the results of the survey results are. However, the results indicate that a majority of caregivers argue that they do not treat patients that are in need of this treatment. Another issue seems to be that there is no product available, but mostly they also warrant studies to prove safety and efficacy. However, a lot of caregivers have come into contact with patients/families that have requested CBD treatment. Conclusion: More placebo-controlled studies of CBD are needed, where it is also taken in account for these drug-drug interactions that have been shown and that there might be certain subgroups of epilepsy that benefit more than others. The low response rate in our survey may indicate low interest for the topic. Or perhaps it will take some more years for interest to grow with the accompaniment of more compelling evidence.en_US
dc.identifier.urihttps://hdl.handle.net/10037/13505
dc.language.isoengen_US
dc.publisherUiT Norges arktiske universiteten_US
dc.publisherUiT The Arctic University of Norwayen_US
dc.rights.accessRightsopenAccessen_US
dc.rights.holderCopyright 2018 The Author(s)
dc.rights.urihttps://creativecommons.org/licenses/by-nc-sa/3.0en_US
dc.rightsAttribution-NonCommercial-ShareAlike 3.0 Unported (CC BY-NC-SA 3.0)en_US
dc.subject.courseIDMED-3950
dc.subjectHealth scienceen_US
dc.subjectMedicineen_US
dc.subjectVDP::Medisinske Fag: 700en_US
dc.subjectVDP::Medical disciplines: 700en_US
dc.titleCannabinoid therapy for Epilepsy : A literature review and a survey among neuro-paediatriciansen_US
dc.typeMaster thesisen_US
dc.typeMastergradsoppgaveen_US


Tilhørende fil(er)

Thumbnail
Thumbnail

Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel

Attribution-NonCommercial-ShareAlike 3.0 Unported (CC BY-NC-SA 3.0)
Med mindre det står noe annet, er denne innførselens lisens beskrevet som Attribution-NonCommercial-ShareAlike 3.0 Unported (CC BY-NC-SA 3.0)